@phdthesis{Pickel2020,
  author    = {Pickel, Simone},
  title     = {Role of the β subunit of L-type calcium channels in cardiac hypertrophy},
  doi       = {10.25972/OPUS-19282},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-192829},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2020},
  abstract  = {L-type calcium channels (LTCCs) control crucial physiological processes in cardiomyocytes such as the duration and amplitude of action potentials, excitation-contraction coupling and gene expression, by regulating the entry of Ca2+ into the cells. Cardiac LTCCs consist of one pore-forming α1 subunit and the accessory subunits Cavβ, Cavα2δ and Cavγ. Of these auxiliary subunits, Cavβ is the most important regulator of the channel activity; however, it can also have LTCC-independent cellular regulatory functions. Therefore, changes in the expression of Cavβ can lead not only to a dysregulation of LTCC activity, but also to changes in other cellular functions. Cardiac hypertrophy is one of the most relevant risk factors for congestive heart failure and depends on the activation of calcium-dependent prohypertrophic signaling pathways. However, the role of LTCCs and especially Cavβ in this pathology is controversial and needs to be further elucidated. Of the four Cavβ isoforms, Cavβ2 is the predominant one in cardiomyocytes. Moreover, there are five different splice variants of Cavβ2 (Cavβ2a-e), differing only in the N-terminal region. We reported that Cavβ2b is the predominant variant expressed in the heart. We also revealed that a pool of Cavβ2 is targeted to the nucleus in cardiomyocytes. The expression of the nuclear Cavβ2 decreases during in vitro and in vivo induction of cardiomyocyte hypertrophy and overexpression of a nucleus-targeted Cavβ2 completely abolishes the in vitro induced hypertrophy. Additionally, we demonstrated by shRNA-mediated protein knockdown that downregulation of Cavβ2 enhances the hypertrophy induced by the α1-adrenergic agonist phenylephrine (PE) without involvement of LTCC activity. These results suggest that Cavβ2 can regulate cardiac hypertrophy through LTCC-independent pathways. To further validate the role of the nuclear Cavβ2, we performed quantitative proteome analyses of Cavβ2-deficient neonatal rat cardiomyocytes (NRCs). The results show that downregulation of Cavβ2 influences the expression of various proteins, including a decrease of calpastatin, an inhibitor of the calcium-dependent cysteine protease calpain. Moreover, downregulation of Cavβ2 during cardiomyocyte hypertrophy drastically increases calpain activity as compared to controls after treatment with PE. Finally, the inhibition of calpain by calpeptin abolishes the increase in PE-induced hypertrophy in Cavβ2-deficient cells. These results suggest that nuclear Cavβ2 has Ca2+- and LTCC-independent functions during the development of hypertrophy. Overall, our results indicate a new role for Cavβ2 in antihypertrophic signaling in cardiac hypertrophy.},
  subject      = {Herzhypertrophie},
  language  = {en}
}
@phdthesis{Fetting2011,
  author    = {Fetting, Doreen [verh: Korb]},
  title     = {Novel Cav1.2 and PMCA4b interacting PDZ domain containing proteins},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-66440},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {The voltage -gated calcium channel, Cav1.2, and the plasma membrane calcium ATPase, PMCA4b, play important roles in excitable and non-excitable cells. The central function of Cav1.2 is to regulate the calcium entry into cells upon depolarization, while PMCA4b is responsible for calcium extrusion and has an influence on cellular calcium homeostasis. Both proteins control fundamental functions in the heart and brain, but the specific functions and the precise mechanisms are still investigated. In order to identify new interaction partners that may regulate the activities of the Cav1.2 and the PMCA4b, we used three independent assays and co-localization studies. The assays, which were used are PDZ domain arrays (testing 124 different PDZ domains), GST pull-downs, and conventional immunoprecipitation assays. In the PDZ arrays, strongest interactions with Cav1.2 and PMCA4b were found for the PDZ domains of MAST-205, MAGI-1, MAGI-2, MAGI-3, and ZO-1. Additionally, we established interactions between Cav1.2 and the PDZ domains of NHERF1/2, Mint-2, and CASK. PMCA4b was observed to interact with Mint-2, and its interactions with Chapsyn-110 and CASK were confirmed. Furthermore, we validated interaction of Cav1.2 and PMCA4b with NHERF1, CASK, MAST-205 and MAGI-3 via immunoprecipitation. We also demonstrated direct interaction of the C-terminus of Cav1.2 and the PDZ domain of nNOS. We assumed that nNOS overexpression would reduce Ca2+ influx through Cav1.2. To address this question, we measured Ca2+ currents in stably transfected HEK 293 cells expressing the Cav1.2 (α1b and β2a subunit of the smooth muscle L-type calcium channel) and nNOS. It has been shown that NO modulates ion channel activity by nitrosylation of sulfhydryl groups on the channel protein. So we propose that the interaction between the C-terminus of Cav1.2 and the PDZ domain of nNOS inhibits the currents by an S-nitrosylation of the channel protein. All these interactions connect both proteins to signaling networks involved in signal transmission, cell adhesion, and apoptosis, which may help provide new hints about the physiological functions of Cav1.2 and PMCA4b in intra- and intercellular signaling.},
  subject      = {Calciumkanal},
  language  = {en}
}